Oireachtas Health Committee seek age restrictions on e-cigarettes and ban on flavourings

Regulations
Jul.19.2022
The committee asked the Minister for Health to look at other countries where ages for vaping and smoking are 21.

A BAN ON flavoured e-cigarettes, e-cigarette ads on social media and bright packaging are just some of the restrictions recommended in a report on pre-legislative scrutiny on a  public health bill published on the weekend.

Oireachtas Health Committee seek age restrictions on e-cigarettes and ban on flavourings

 

The Oireachtas joint committee on health compiled suggestions for the Public Health (Tobacco and Nicotine Inhaling Products) Bill 2019 after meeting with health specialists and representatives of the vaping industry.

 

A key recommendation was that the bill should regulate the flavouring of e-cigarettes and that all flavours except for tobacco, should be strictly prohibited so as not to entice minors.

 

Speaking to the committee, the Irish Heart Foundation called e-cigarette flavours marketing tools “that are almost exclusively directed at young people because if young people are not addicted, there is no business model.”

 

The committee has stated that the Minister for Health should review international studies to consider increasing the age for buying tobacco and nicotine-inhaling products  to 21.

 

Also giving evidence to the committee, the Royal College of Physicians in Ireland (RCPI) stated that teenagers are more likely to use flavoured nicotine products than other age groups.

 

However, the RCPI also told the committee that a recent study examining the effects of a similar ban in Finland did not report a significant change in e-cigarette use post introduction.

 

Many of the proposals made by the committee indicate a desire to treat e-cigarettes more like traditional cigarettes, such as a move to introduce plain packaging rather than what the Irish Cancer Society has called “cartoon-type packaging”.

 

According to a 2019 European School Survey Project on Alcohol and Other Drugs (ESPAD) vaping among young people is now more common than smoking and more young people aged 12-17 years have tried vaping (22%) compared to adults (14%).

 

The survey also found that in 15 and 16 year olds, almost four in 10 students (39%) had tried e-cigarettes and almost one in 5 (18%) were current users.

 

However, the sale of e-cigarettes to under-18s is still not against the law despite the fact that public health officials as well as representatives of the vaping industry have been advocating for it for years.

 

In response to the report’s publication Vape Business Ireland stated that the complexity of the suggestions would only delay the bill and the under-18s ban.

 

It also claimed that the committee referred to “outdated evidence, as well as research which falls short of international standards”.

 

Another measure in the report would ban the sale of e-cigarettes from temporary units such as kiosks, stalls or marquees at festivals and introduce a license for approved sellers.

 

The report also urges that the bill  contain measures to ban all forms of e-cigarette advertising on billboards, online on all social media platforms, and influencer marketing methods.

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Italian Financial Police Seize 4.3 Million E-Cigarettes and Smoking Accessories; 28 Reported to Judicial Authorities Across Operations
Italian Financial Police Seize 4.3 Million E-Cigarettes and Smoking Accessories; 28 Reported to Judicial Authorities Across Operations
Italy's Guardia di Finanza announced on October 28 that officers in Latina province had seized approximately 4.3 million e-cigarettes and smoking accessories at an unauthorized warehouse in an operation involving restrictions on the possession and sale of tobacco-related products. Another 300,000 suspected counterfeit or unsafe items were confiscated during separate inspections, bringing total seizures across the operations to more than 4.6 million products. Twenty-eight people were reported to judicial authorities over suspected smuggling and counterfeiting offenses. Officials did not disclose separate vape quantities, the value of the merchandise or alleged violations associated with individual brands.
Enforcement
Oct.29
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
French vaping company Kumulus Vape reported first-half 2026 revenue of €25.5 million, down 8.3% year over year, as its core B2B distribution business fell 11% to €21.6 million. B2C and store-network revenue rose 5.6% and 17.8%, respectively. Commercial margin increased to 26.3% from 21.7%, while net profit rose 24.1% to €0.8 million. The company attributed the profitability improvement to catalog optimization, logistics restructuring and the ramp-up of Labster, its in-house production unit for proprietary brands.
Market
Sep.17 by 2Firsts Perspectives
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
KIWI has launched the Spark 2 and Spark 2 Pro refillable pod systems in Germany at official prices of €18 and €29, respectively. Spark 2 uses an 800mAh removable lithium-ion battery in a pen-style body, while Spark 2 Pro features a 1,400mAh removable battery, a box-shaped design and vibration feedback every 20 puffs. Both devices use the same 2ml Spark V2 pods in 0.8Ω and 1.2Ω versions, with AirSync airflow adjustment and a choice between Cotton Tips and conventional Drip Tips. The new pods also remain compatible with the original KIWI Spark.
News
Sep.29 by 2Firsts Perspectives